ONCOLOGY · KASDAP HEALTHCARE
Cancer is India's second leading cause of disease-related mortality. Understanding oncology supportive care medicines and the role of quality pharmaceutical supply chains in cancer management is critical for every healthcare professional.
Cancer in India: A Growing Epidemic
India faces a rapidly growing cancer burden, with an estimated 1.4 million new cancer cases diagnosed annually and over 900,000 cancer-related deaths each year. The most prevalent cancers in India include oral cavity cancer, breast cancer, cervical cancer, lung cancer, and colorectal cancer.
Late diagnosis remains a critical challenge — over 70% of Indian cancer patients present with advanced-stage disease, significantly limiting curative treatment options and increasing reliance on palliative and supportive care medicines. The availability and affordability of these medicines is a pressing public health priority.
Oncology Supportive Care: The Critical Pharmaceutical Segment
While chemotherapy, targeted therapy, and immunotherapy are the primary anti-cancer modalities, supportive care medicines manage the side effects of cancer treatment and maintain patients' quality of life during therapy. These medicines are as critical as the anti-cancer agents themselves.
Antiemetics: Managing Chemotherapy-Induced Nausea
Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing and treatment-limiting side effects of cancer chemotherapy. Effective antiemetic prophylaxis is essential for patient wellbeing and treatment compliance.
- 5-HT3 antagonists: Ondansetron, Granisetron, and Palonosetron are the cornerstone of CINV prophylaxis, particularly for acute nausea within 24 hours of chemotherapy
- NK1 receptor antagonists: Aprepitant and Fosaprepitant extend antiemetic protection to delayed CINV (24–120 hours post-chemotherapy) in highly emetogenic regimens
- Dexamethasone: Corticosteroids remain a key component of multimodal antiemetic regimens across emetogenic risk categories
Granulocyte Colony-Stimulating Factors (G-CSFs)
Febrile neutropenia — life-threatening infection complicating chemotherapy-induced bone marrow suppression — is a major cause of treatment delays and hospitalisation. G-CSFs (Filgrastim, Pegfilgrastim) stimulate neutrophil production and are used prophylactically with highly myelosuppressive regimens and therapeutically in established febrile neutropenia.
Pain Management in Cancer
Cancer pain affects over 70% of patients with advanced cancer. The WHO Analgesic Ladder provides the framework for cancer pain management:
- Step 1 (mild pain): Non-opioid analgesics — Paracetamol, NSAIDs
- Step 2 (moderate pain): Weak opioids — Tramadol, Codeine
- Step 3 (severe pain): Strong opioids — Morphine, Oxycodone, Fentanyl
Corticosteroids in Oncology
Dexamethasone and Prednisolone play multiple roles in cancer care: as components of chemotherapy regimens (lymphoma, myeloma), antiemetic combinations, cerebral oedema management in brain metastases, appetite stimulation in cachexia, and anti-inflammatory support in immune-related adverse events from immunotherapy.
Bisphosphonates: Bone Protection in Cancer
Bone metastases from breast, prostate, and lung cancers cause significant pain, fracture risk, and hypercalcaemia. Zoledronic acid (IV) and Denosumab are the primary agents for preventing skeletal-related events in patients with bone metastases. Bisphosphonates also have direct anti-tumour effects in certain haematological malignancies.
Oral Cancer: India's Unique Challenge
India has one of the highest rates of oral cavity cancer globally, driven by the widespread use of tobacco in forms unique to the subcontinent — gutka, khaini, paan masala, and bidis. Oral submucous fibrosis — a precancerous condition caused by arecanut chewing — affects millions of Indians. Early detection and treatment of these lesions is critical to reducing India's oral cancer mortality.
The Role of Quality in Oncology Supportive Care
In patients already immunocompromised by cancer and chemotherapy, the quality of supportive care medicines is not merely a regulatory concern — it is a matter of life and death. A substandard antiemetic that fails to control CINV can lead to dehydration, treatment delays, and chemotherapy dose reductions that compromise cancer outcomes. WHO-GMP certified manufacturing is essential across every oncology supportive care product.
Kasdap Healthcare's Commitment to Oncology Support
Kasdap Healthcare stocks a range of oncology supportive care medicines including antiemetics, analgesics, corticosteroids, and nutritional support products — all sourced from WHO-GMP certified manufacturers to ensure consistent quality for every cancer patient in our distribution network.
Explore our complete product portfolio
